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 BACKGROUND 
 
 
 
 
  MATERIAL AND METHODS 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
• Oclacitinib plasmatic concentrations showed an important 
variability. 
• Every dog had a positive response to the treatment. 
• Only 33% of atopic dogs show an improvement in CADESI index. 
However, in PVAS score, 91.6% show an improvement.  
• It cannot be assess a correlation between plasmatic levels of 
oclacitinib and clinical response. 
OBJECTIVES 
 
         To determine oclacitinib plasmatic 
concentrations in atopic dogs after 30 
days of treatment. 
 
         To assess a possible correlation 
between clinical improvement and 
plasmatic levels of oclacitinib. 
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Oclacitinib is a Janus kinase (JAK) 
inhibitor1. JAK1-dependent cytokines (IL-2, 
IL-4, IL-6, IL-31 and IL-13) are involved in 
inflammatory processes and allergies, and 
are also important in pruritus pathways2.  
 
Despite oclacitinib is a safe and effective 
drug in canine atopic dermatitis (CAD) 
treatment, some dogs do not show a 
positive clinical response. 
Figure 2. Body sites evaluated in CADESI-4 3. 
CASE PLASMATIC LEVELS 
OF OCLACITINIB D30 
(ng/mL) 
CADESI 
REDUCTION 
(%) 
PVAS 
REDUCTION 
(%) 
Oc1 150,9 70 52,94 
Oc2 447,1 55,55 56,25 
Oc3 294,9 28,12 75 
Oc4 321,1 43,47 57,14 
Oc5 95,4 55 60 
Oc6 356,1 40,80 100 
Oc7 35,5 40,85 38 
Oc8 8,8 46,15 64,29 
Oc9 344,2 34,37 57,14 
Oc12 370,5 46,77 60 
Oc13 152,2 100 100 
Oc14 302,7 34,37 60 
 Figure 3. Clinical evolution in CADESI and PVAS scores. 
RESULTS 
 
Table 1. Oclacitinib plasma levels at day 30 and clinical 
reduction in CADESI and PVAS scores. 
Diagnosis 
of CAD 
Oclacitinib treatment 
0.4-0.6 mg/kg PO q24h 
Analysis samples:  
HPLC-MS 
Inclusion dogs 
CADESI and  PVAS 
Plasma samples 
Final visit 
CADESI and  PVAS 
Plasma samples 
D0 D30 
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Figure 1. Mechanism of action of oclacitinib  (CAD 
Immunotherapeutic, 2015. Zoetis) 
  
